EUCTR2012-003937-41-PL进行中（未招募）不适用
Phase 2, Observer-Blind, Placebo-Controlled, Randomized, Multi-Center Extension Study to Evaluate the Safety and Immunogenicity of a Booster Dose of a MenABCWY Vaccine Administered 24 Months Following the Primary Series to Adolescents and Young Adults Who Participated in V102_03
GSK Vaccines S.r.l0 个研究点目标入组 484 人开始时间: 2013年12月2日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 484
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Males and females that received both vaccinations and completed the Study Termination visit in the primary study, V102_03;
- •2. Individuals or the individual’s parents or legal guardian who have given written consent after the nature of the study has been explained according to local regulatory requirements;
- •3. Individuals who have given written assent as required by local regulations after the nature of the study has been explained to them according to local regulatory requirements;
- •4. Individuals in good health as determined by the outcome of medical history, physical examination and clinical judgment of the investigator;
- •5. Individuals and/or or the individual’s parents or legal guardian who can comply with study procedures and are available for follow-up.
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range: 484
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 152
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1. History of any meningococcal vaccine administration other than the vaccination administered in the primary study, V102_03;
- •2. Current or previous, confirmed or suspected disease caused by N. meningitidis;
- •3. Household contact with and/or intimate exposure to an individual with any laboratory confirmed N. meningitidis infection within 60 days of enrollment;
- •4. History of severe allergic reactions after previous vaccinations or hypersensitivity to
- •any vaccine component;
- •5. All sexually active females that have not used an acceptable contraceptive method(s)” for at least 2 months prior to study entry. Acceptable birth control methods are defined as one or more of the following:
- •a. Hormonal contraceptive (such as oral, injection, transdermal patch, implant, cervical ring)
- •b. Barrier (condom with spermicide or diaphragm with spermicide) each and every time during intercourse
- •c. Intrauterine device (IUD)
- •d. Monogamous relationship with vasectomized partner. Partner must have been vasectomized for at least six months prior to the subject’s study entry;
- •6. Sexually active females that refuse to use to an acceptable contraceptive method”
- •through to 3 weeks following the study vaccination;
- •7. Female subjects with a positive pregnancy test prior to the study vaccine being
- •administered;
- •8. Nursing (breastfeeding) mothers;
- •9. Individuals with a history of illness or with an ongoing illness that, in the opinion of the investigator, may pose additional risk to the subject if he/she participates in the study;
- •10. Any serious, chronic, or progressive disease (e.g., neoplasm, diabetes, cardiac disease, hepatic disease, progressive neurological disease or seizure disorder; autoimmune disease, HIV infection or AIDS, blood dyscrasias, bleeding diathesis, signs of cardiac or renal failure, or severe malnutrition);
- •11. Subjects who required chronic administration (defined as more than 14 days) of immunosuppressants or other immune-modifying drugs within six months prior to the study vaccination. (For corticosteroids, this means prednisone, or equivalent, = 20mg/day. Inhaled and topical steroids are allowed).
- •12. Receipt of blood, blood products and/or plasma derivatives, or a parenteral immunoglobulin preparation within the previous 90 days;
- •13. Individuals participating in any clinical trial with another investigational product 30 days prior to first study visit or intent to participate in another clinical study at any time during the conduct of this study;
- •14. Administration or planned administration, of any vaccine not foreseen by the study protocol within 30 days prior study vaccination, and up to 30 days after the vaccination (with the exception of any licensed influenza vaccine which may be administered >14 days preceding or >14 days following the study vaccination);
- •15. Individuals who study personnel or immediate family members of study personnel including brother, sister, child, parent, or the spouse.
- •16. Individuals who have experienced moderate or severe acute infection and/or feve (defined as temperature 38°C) within 3 days prior to enrolment.
- •17. Who have received systemic antibiotic treatment within 7 days prior to enrolment.
研究者
相似试验
已完成
1 期
A Study to Evaluate the Safety and Immunogenicity of COVID-19 Vaccine (IVX-411) in Healthy AdultsSARS-CoV-2 ( COVID-19)Respiratory - Other respiratory disorders / diseasesInfection - Other infectious diseasesACTRN12621000738820Icosavax Inc.84
已完成
不适用
Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study Evaluating the Efficacy and Safety of Lecithinized Superoxide Dismutase Nebulizer (PC-SOD NE) in Adult Patients with Moderate Idiopathic Pulmonary Fibrosisidiopathic pulmonary fibrosisJPRN-UMIN000009572TT Bio-Pharma Co., Ltd.96
已完成
不适用
Phase 2, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Diclofenac Sodium Eye-Drops (LT-0303) in Patients with dry eye syndromedry eye syndromeJPRN-UMIN000021601TT Bio-Pharma Co., Ltd.20
招募中
1 期
Phase 2, Randomized, Double-Blind, Placebo-Controlled, Nested Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of ARCT-810 in Adolescent and Adult Participants with Ornithine Transcarbamylase DeficiencyMedDRA version: 21.1Level: LLTClassification code 10013373Term: Disorders of urea cycle metabolismSystem Organ Class: 100000004850Ornithine transcarbamylase deficiencyEUCTR2021-001081-38-ITArcturus Therapeutics, Inc.24
已完成
2 期
Phase 2, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Diclofenac Sodium Eye-Drops (LT-4002) in Patients with dry eye syndromedry eye syndromeJPRN-UMIN000036467TT Bio-Pharma Co., Ltd.240